Sex, Gender, and the Regulation of Prescription Drugs: Omissions and Opportunities

The regulation of prescription drugs is an important health, safety, and equity issue. However, regulatory processes do not always consider evidence on sex, gender, and factors such as age and race, omissions that advocates have highlighted for several decades. Assessing the impact of sex-related factors is critical to ensuring drug safety and efficacy for females and males, and for informing clinical product monographs and consumer information. Gender-related factors affect prescribing, access to drugs, needs and desires for specific prescribed therapies. This article draws on a policy-research partnership project that examined the lifecycle management of prescription drugs in Canada using a sex and gender-based analysis plus (SGBA+) lens. In the same time period, Health Canada created a Scientific Advisory Committee on Health Products for Women, in part to examine drug regulation. We report on grey literature and selected regulatory documents to illustrate the extent to which sex and gender-based analysis plus (SGBA+) is utilized in regulation and policy. We identify omissions in the management of prescription drugs, and name opportunities for improvements by integrating SGBA+ into drug sponsor applications, clinical trials development, and pharmacovigilance. We report on recent efforts to incorporate sex disaggregated data and recommend ways that the management of prescription drugs can benefit from more integration of sex, gender, and equity.

[1]  Alice Li,et al.  A Sex- and Gender-Based Analysis of Adverse Drug Reactions: A Scoping Review of Pharmacovigilance Databases , 2022, Pharmaceuticals.

[2]  L. Greaves,et al.  Sex, Gender and Health: Mapping the Landscape of Research and Policy , 2022, International journal of environmental research and public health.

[3]  R. Shansky,et al.  Considering sex as a biological variable will require a global shift in science culture , 2021, Nature Neuroscience.

[4]  B. Bierer,et al.  Committing to the Inclusion of Diverse Populations in Clinical Research , 2020, Therapeutic Innovation & Regulatory Science.

[5]  Natalie Hemsing,et al.  Sex and Gender Interactions on the Use and Impact of Recreational Cannabis , 2020, International journal of environmental research and public health.

[6]  J. Krska,et al.  Making medicines safer: analysis of patient reports to the UK’s Yellow Card Scheme , 2019, Expert opinion on drug safety.

[7]  Feyza Sancar.  Another Option for Hypoactive Sexual Desire. , 2019, Journal of the American Medical Association (JAMA).

[8]  Alla Yakerson.  Women in clinical trials: a review of policy development and health equity in the Canadian context , 2019, International Journal for Equity in Health.

[9]  D. Kowalski,et al.  No Dose Adjustment for Isavuconazole Based on Age or Sex , 2019, Antimicrobial Agents and Chemotherapy.

[10]  Elemental Impurities Q3DR.  INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL STUDIES E8(R1) , 2019 .

[11]  Lucie M. Bucci.  Health Canada , 2019, The Grants Register 2022.

[12]  J. Desai,et al.  Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood , 2018, Cancer Chemotherapy and Pharmacology.

[13]  O. Levy,et al.  First International Precision Vaccines Conference: Multidisciplinary Approaches to Next-Generation Vaccines , 2018, mSphere.

[14]  E. V. van Puijenbroek,et al.  Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors , 2018, Drug Safety.

[15]  Anna Nowogrodzki.  Clinical research: Inequality in medicine , 2017, Nature.

[16]  V. Serebruany,et al.  Aspirin in the Food and Drug Administration Adverse Event Reporting System: Missing Demographics and Underreporting , 2017, TH Open.

[17]  L. Calzetta,et al.  Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine , 2017, EBioMedicine.

[18]  W. Wisemandle,et al.  Pharmacokinetic and Pharmacodynamic Equivalence of Epoetin Hospira and Epogen After Single Subcutaneous Doses to Healthy Male Subjects. , 2016, Clinical therapeutics.

[19]  David Peddie,et al.  Adverse drug event reporting systems: a systematic review. , 2016, British journal of clinical pharmacology.

[20]  T. Babor,et al.  Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use , 2016, Research Integrity and Peer Review.

[21]  C. Johannessen Landmark,et al.  Pharmacotherapy in epilepsy – does gender affect safety? , 2016, Expert opinion on drug safety.

[22]  A. D'Ursi,et al.  Is it time to integrate sex and gender into drug design and development? , 2015, Future medicinal chemistry.

[23]  Jonathan C. Craig,et al.  Clinical trials in children. , 2015, British journal of clinical pharmacology.

[24]  D. Matsui.  Ethics of Studies of Drugs in Pregnancy , 2015, Pediatric Drugs.

[25]  Guideline on the investigation of subgroups in confirmatory clinical trials , 2014 .

[26]  E. Unger,et al.  Zolpidem and driving impairment--identifying persons at risk. , 2013, The New England journal of medicine.

[27]  J. Montastruc,et al.  Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors , 2013, European Journal of Clinical Pharmacology.

[28]  S. Klein,et al.  Personalized vaccinology: one size and dose might not fit both sexes. , 2013, Vaccine.

[29]  R. Shah,et al.  ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies. , 2013, British journal of clinical pharmacology.

[30]  B. Kuehn.  FDA warning: Driving may be impaired the morning following sleeping pill use. , 2013, JAMA.

[31]  J. Tokars,et al.  A cluster of nonspecific adverse events in a military reserve unit following pandemic influenza A (H1N1) 2009 vaccination-possible stimulated reporting? , 2012, Vaccine.

[32]  H. Davies,et al.  HPV Vaccine Recommendations , 2012, Pediatrics.

[33]  J. Fisher,et al.  Challenging assumptions about minority participation in US clinical research. , 2011, American journal of public health.

[34]  B. Zarowitz,et al.  Focus on statin safety concerns. , 2011, Geriatric Nursing.

[35]  G. Wilding,et al.  Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients , 2011, Cancer Chemotherapy and Pharmacology.

[36]  R. Sataloff.  Proton pump inhibitors: Adverse effects. , 2010, Ear, nose, & throat journal.

[37]  Anthony Avery,et al.  Adverse Drug Reaction Reporting in the UK , 2010, Drug safety.

[38]  J. Fisher,et al.  Sex, gender, and pharmaceutical politics: From drug development to marketing. , 2010, Gender medicine.

[39]  A. Egberts,et al.  Recurrence of Adverse Drug Reactions following Inappropriate Re-Prescription , 2010, Drug safety.

[40]  Teresa K. Woodruff,et al.  Sex bias in trials and treatment must end , 2010, Nature.

[41]  D. Goldberg,et al.  Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. , 2010, American journal of public health.

[42]  H. Mellor,et al.  Gender differences in drug toxicity. , 2010, Trends in pharmacological sciences.

[43]  A. Lippman.  The Inclusion of Women in Clinical Trials: Are We Asking the Right Questions? , 2006 .

[44]  L. Hazell,et al.  Under-Reporting of Adverse Drug Reactions , 2006, Drug safety.

[45]  Chikayuki Naito,et al.  Ethnic Factors in the Acceptability of Foreign Clinical Data , 1998 .

[46]  J. R. Williams,et al.  Direct-to-consumer advertising of prescription drugs. , 1995, Journal of health care marketing.

[47]  D. Federman,et al.  NIH Revitalization Act of 1993 Public Law 103-43 , 1994 .

[48]  Lars Mosesson,et al.  Are we asking the right questions , 1990 .